ClinicalTrials.gg
Not yet recruitingNCT06346925Updated Apr 4, 2024

Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects.

A Phase 1 interventional study of Herombopag Olamine Tablets in Adult Patients With Chronic Primary ITP and Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study was designed as a single-center, randomized, open, two-cycle, cross-over trial. It is planned to enroll 18 healthy subjects

02

Conditions studied

  • Adult Patients With Chronic Primary ITP
  • Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Male or female aged 18-45 at screening (both inclusive)
  3. (BMI) at 19.0\~28.0 kg/m2 (including critical value)
  4. Subjects who are considered to be generally healthy, based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator
  5. Subjects (including male subjects) are willing to have no birth plan and voluntarily adopt effective measures and no sperm donation plan from 2 weeks before screening to 3 months after the last administration of the study drug, and ensure the use of one or more contraceptive methods during sexual life during this period

Exclusion criteria

Exclusion Criteria:

  1. People who have or are currently suffering from any clinically serious medical conditions such as circulatory, endocrine, neurological, digestive, respiratory, hematology, immunological, psychiatric and metabolic abnormalities within the previous year or any other disease that can interfere with the test results;.
  2. People with a history of deep vein thrombosis or other thrombotic disorders.
  3. Prolonged on 12- at screening (450 ms > men and >470 ms) (corrected for Fridericia's formula or other abnormalities determined by the clinician)。
  4. Those who test positive for surface antigen, antibody, syphilis antibody, and antibody
  5. Those with a positive pregnancy test.
  6. Allergies, such as those with a known history of allergy to two or more substances; or anyone allergic to Hydrazopag Ethanolamine tablets and their .
  7. Those who had undergone surgery within 4 weeks prior to screening, or who planned to undergo surgery during the study.
  8. Has taken any prescription, over-the-counter, herbal or health product within 14 days prior to screening or dosing.
  9. Those who participated in any clinical trial and used any drug within 3 months prior to screening.
  10. Blood donation (or blood loss) and blood donation (or blood loss) ≥400 mL within 3 months before screening, or receiving blood transfusion
  11. Those who have special dietary requirements and cannot comply with the diet and corresponding regulations provided by the test.
  12. Those who smoked an average of 5 or more cigarettes per day in the month prior to screening or could not stop using any tobacco products during the test period.
  13. Those who consumed an average of more than 14 units of alcohol per week (1 unit of alcohol ≈360mL beer or 45mL spirits with 40% alcohol content or 150mL wine) in the three months before screening, or who could not abrol during the test period.
  14. Positive alcohol test.
  15. Those who have a history of drug abuse, drug dependence or positive urine drug screening within 3 months prior to screening.
  16. Patients with a history of needle fainting or blood fainting, or those who cannot tolerate venous puncture blood collection.
  17. People with difficulty swallowing tablets
  18. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Take Herombopag Olamine Tablets 7.5mg 30min after high-fat meal in the first cycle. in the second cycle, take Herombopag Olamine Tablets 7.5mg on an empty stomach

    Drug: Herombopag Olamine Tablets

  • Experimental
    Treatment group B

    Take Herombopag Olamine Tablets 7.5mg 30min on an empty stomach in the first cycle. In the second cycle, take Herombopag Olamine Tablets 7.5mg 30min fter high-fat meal

    Drug: Herombopag Olamine Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 0hour to 120hours after the last dosing

  2. AUC0-t

    Time frame: 0hour to 120hours after the last dosing

  3. AUC0-∞

    Time frame: 0hour to 120hours after the last dosing

Secondary outcomes

  1. Tmax

    Time frame: 0hour to 120hours after the last dosing

  2. t1/2

    Time frame: 0hour to 120hours after the last dosing

  3. CL/F

    Time frame: 0hour to 120hours after the last dosing

  4. V/F

    Time frame: 0hour to 120hours after the last dosing

  5. Incidence and severity of adverse events (AEs)

    Time frame: from screening to 120 hours after the last dosing

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Jul 2024, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2024
First posted
Apr 4, 2024
StartEst.
Apr 2024
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06346925
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Apr 2024 (estimated)
Primary completion
Jul 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Apr 4, 2024

Study contacts

Sheng Feng
Contact
sheng.feng@hengrui.com
+86-0518-82342973
Weijie Kong
Contact
hongda.lin@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion